NTILF (Neurotech International) Other Stockholders Equity: $-0.00 Mil (As of Dec. 2025)


NTILF Neurotech International Ltd NTILF
34 GF Score
Price $0.00
! 1 Warning Sign
View Full Analysis

What is Neurotech International Other Stockholders Equity?

Neurotech International NTILF 34 Other Stockholders Equity is $-0.00 Mil as of Dec. 2025. GuruFocus rates NTILF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Neurotech International's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $-0.00 Mil.

Neurotech International's quarterly Other Stockholders Equity increased from Dec. 2024 ($0.00 Mil) to Jun. 2025 ($0.00 Mil) but then declined from Jun. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil).

Neurotech International's annual Other Stockholders Equity declined from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($-0.00 Mil) but then increased from Jun. 2024 ($-0.00 Mil) to Jun. 2025 ($0.00 Mil).

Neurotech International Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Neurotech International's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurotech International Other Stockholders Equity Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only -0.00 0.00 0.00 -0.00 0.00

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 -0.00
NTILF
34GF Score
Neurotech International Ltd NTILF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurotech International Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Neurotech International (NTILF) has a Other Stockholders Equity of $-0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Neurotech International and its competitors.
Is Neurotech International's Other Stockholders Equity too high?
Neurotech International's current Other Stockholders Equity is $-0.00 Mil. Overall, Neurotech International has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Neurotech International's Other Stockholders Equity compare to VRTX and REGN?
Neurotech International's Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Neurotech International and its competitors. Neurotech International's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (NTILF) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. Neurotech International's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Neurotech International (NTILF), the current Other Stockholders Equity is $-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurotech International Business Description

Other Exchanges NTI:Australia
Address 55 Collins Street, Suite 102, Level 1, Melbourne, VIC, AUS, 3000
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
34GF Score

Get the complete analysis for NTILF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price